Friedman Paul A
SEC-identified person · CIK 1236927 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Prelude Therapeutics Inc PRLD | Director | filed 2020–2026 |
| Synta Pharmaceuticals Corp SNTA | Director · Chief Executive Officer | filed 2014–2026 |
| Alexion Pharmaceuticals, INC. alxn | Director | filed 2017–2021 |
| Incyte Corp INCY | Director · Chief Executive Officer | filed 2006–2020 |
| Dare Bioscience, Inc. DARE | Director | filed 2014–2017 |
| Verastem, Inc. VSTM | Director | filed 2014–2016 |
| Auxilium Pharmaceuticals INC AUXL | Director | filed 2010–2015 |
| Durata Therapeutics, Inc. DRTX | Director | filed 2013–2014 |
| Sirtris Pharmaceuticals, Inc. SIRT | Director | filed 2008–2008 |
| Bausch & Lomb INC BOL | Director | filed 2007–2007 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.